This AOP is licensed under a Creative Commons Attribution 4.0 International License.
Coronaviral replication / RNA genome transcription leading to thrombosis
Point of Contact
- Shihori Tanabe
- Arthur Author
|Author status||OECD status||OECD project||SAAOP status|
|Under development: Not open for comment. Do not cite|
This AOP was last modified on April 05, 2021 18:16
|Oxidative Stress||March 12, 2020 14:26|
|Coagulation||March 25, 2021 20:17|
|Thrombosis||March 25, 2021 19:52|
|Coronaviral replication / RNA genome transcription||March 28, 2021 20:25|
|Increased viral entry and gene expression||March 30, 2021 22:01|
|RNA genome transcription leads to Oxidative Stress||March 25, 2021 19:55|
|Oxidative Stress leads to Coagulation||March 25, 2021 19:54|
|Coagulation leads to Thrombosis||March 26, 2021 01:14|
|Increased viral entry and gene expression leads to RNA genome transcription||March 30, 2021 22:06|
|Sars-CoV-2||February 23, 2021 04:50|
Coronavirus disease-19 (COVID-19) is circulating all over the world. To understand and find a way of the COVID-19 treatment, the therapeutic mechanism of COVID-19 is focused on in this Editorial. The pathogenesis of COVID-19 includes molecular networks such as the binding of the membrane proteins, signaling pathways, and RNA replication. The mechanism of infection and targets of the therapeutics are explored and summarized. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a new type of coronavirus causing COVID-19, infects the cells via the binding of the membrane proteins of human cells and is internalized by the cells. The viral genome is replicated by RNA-dependent RNA polymerase (RdRp), followed by the packaging and releasing of the viral particles. These steps can be the main targets for the therapeutics of COVID-19. This AOP379 "Coronaviral replication / RNA genome transcription leading to thrombosis" consists of the molecular initiating event (MIE) as "Coronaviral replication / RNA genome transcription" (KE1847), key events (KEs) as "Oxidative stress" (KE1: KE1392) and "Coagulation" (KE2: KE1845), and adverse outcome (AO) as "thrombosis" (KE1846).
Summary of the AOP
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
|Sequence||Type||Event ID||Title||Short name|
|1||MIE||1738||Increased viral entry and gene expression||Increased viral entry and gene expression|
|2||MIE||1847||Coronaviral replication / RNA genome transcription||RNA genome transcription|
Relationships Between Two Key Events (Including MIEs and AOs)
|RNA genome transcription leads to Oxidative Stress||adjacent||Moderate|
|Oxidative Stress leads to Coagulation||adjacent||Moderate|
|Coagulation leads to Thrombosis||adjacent||High|
|Increased viral entry and gene expression leads to RNA genome transcription||adjacent||High||Moderate|
Life Stage Applicability
|All life stages||Moderate|
|Homo sapiens||Homo sapiens||High||NCBI|
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Considerations for Potential Applications of the AOP (optional)
1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic Coronaviruses. Nature Reviews Microbiology. 2019;17(3):181-192.
2. Chen B, Tian EK, He B, Tian L, Han R, Wang S, et al. Overview of lethal human Coronaviruses. Signal Transduction and Targeted Therapy, 2020;5(1):89.
3. Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini,E, et al. Immune-mediated approaches against COVID-19. Nature Nanotechnology. 2020:15(8):630-45.
4. Blanco Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 181;(5):1036-1045.
5. Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, et al. Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Reports Medicine. 2020:1(4).
6. Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020.
7. Kowalewski J, Ray A. Predicting novel drugs for SARS-CoV-2 using machine learning from a & g 10 million chemical space. Heliyon. 2020;6(8).
6. Tanabe S. The Therapeutic Mechanism of COVID-19. J Clin Med Res. 2020;2(5):1-3. DOI: https://doi.org/10.37191/Mapsci-2582-4333-2(5)-048